Clinical Trials
6
Active:0
Completed:3
Trial Phases
2 Phases
Phase 2:3
Not Applicable:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 2
3 (75.0%)Not Applicable
1 (25.0%)Safety and Efficacy Study of NTC-510 to Treat Pain Following Dental Surgery of Third Molars
Phase 2
Terminated
- Conditions
- Dental Pain
- Interventions
- Drug: NTC-510 capsulesDrug: Placebo CapsulesDrug: NTC-510A Capsules
- First Posted Date
- 2014-06-11
- Last Posted Date
- 2017-06-23
- Lead Sponsor
- NanoSHIFT LLC
- Target Recruit Count
- 52
- Registration Number
- NCT02161354
- Locations
- 🇺🇸
PPD Dental Pain Clinic, Austin, Texas, United States
Study of NanoDOX Hydrogel vs Placebo for Dehisced Surgical Wounds
Not Applicable
Withdrawn
- Conditions
- Dehisced Surgical Wounds
- Interventions
- Drug: placebo hydrogel
- First Posted Date
- 2012-03-07
- Last Posted Date
- 2017-03-13
- Lead Sponsor
- NanoSHIFT LLC
- Registration Number
- NCT01547325
- Locations
- 🇺🇸
Walter Reed National Military Medical Center, Bethesda, Maryland, United States
Open Label Trial of NanoDOX Hydrogel in Orthopedic Trauma Wounds With and Without Vacuum Assisted Closure Therapy
Phase 2
Withdrawn
- Conditions
- Orthopedic Trauma Wounds
- Interventions
- Drug: NanoDOX HydrogelOther: VAC Alone
- First Posted Date
- 2012-01-26
- Last Posted Date
- 2017-06-23
- Lead Sponsor
- NanoSHIFT LLC
- Registration Number
- NCT01518491
- Locations
- 🇺🇸
Walter Reed National Military Medical Center, Bethesda, Maryland, United States
🇺🇸Univeristy of Missouri, Columbia, Missouri, United States
Study to Assess the PK Profile of NanoBUP Capsules Relative to Suboxone
- First Posted Date
- 2010-12-15
- Last Posted Date
- 2017-06-23
- Lead Sponsor
- NanoSHIFT LLC
- Target Recruit Count
- 12
- Registration Number
- NCT01260675
- Locations
- 🇺🇸
Worldwide Clinical Trials, San Antonio, Texas, United States
A Single-Dose Study of an Investigational Capsule Formulation of 2 mg/0.5 mg Buprenorphine/Naloxone
- First Posted Date
- 2009-04-14
- Last Posted Date
- 2017-06-23
- Lead Sponsor
- NanoSHIFT LLC
- Target Recruit Count
- 6
- Registration Number
- NCT00880841
- Locations
- 🇺🇸
CEDRA Clinical Research, Austin, Texas, United States
- Prev
- 1
- 2
- Next
News
No news found